ARWR begins dosing ARO-HBV | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34225 of 34823  at  3/27/2018 1:49:26 PM  by


 In response to msg 34223 by  stencil
view thread

Re: ARWR begins dosing ARO-HBV

One would have to be frankly moronic to believe a Jefferies "research report".

The only thing objectively first in class is Anzalone's ability to constantly raise money despite burning investors on poorly planned research development, for the company and himself.

Jefferies is simply completing the deal. They got the last secondary and made the commission. Anzalone got 500K of shares priced at 0. The buyers that Jefferies lined up now get the opportunity to sell their shares at a guaranteed profit.

Jefferies, on 0 data on TRIM is no more educated on whether TRIM is the new best in class than a punter betting on a novice horse never seen before.

What is definitely not a coincidence is that Jefferies happened to have an independent report ready for release on the day ARWR announced first dosing in a safety P1! Wow it seems a leader in safety to me. Especially with the track record the company has.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 332
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
34226 Re: ARWR begins dosing ARO-HBV stencil 0 3/27/2018 2:11:02 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by